Understand our Platform’s innovative capabilties
At this stage, we’re focused on co-development partnerships, providing select partners with limited early access to our groundbreaking technology.
For proof-of-concept studies, we generally follow an R&D fee-for-service model, with clearly defined project milestones and associated costs.
For projects closer to commercialization, we offer a more flexible approach, which can include technical milestones, phased payments, and discussions around royalty payments for products produced with our photomolecular platform. Additionally, we can negotiate exclusive licenses for specific product categories, ensuring that your investment is fully protected and aligned with your long-term strategic goals.
Our business model varies from licensing the technology to joint ventures and offering customized optogenetics solutions or services to partners in the biotech and pharma industries. This flexibility allows us to adapt our approach to meet the specific requirements and strategic objectives of each partner.
We are actively exploring commercial partnerships. Stay tuned for more details in the months ahead.
Please contact partners@prolific-machines.com to learn more about co-developing the future of biology with us. A member of our team will quickly be in touch to explore opportunities.
We’ll be able to share more details on pricing as we commercialize partnerships across biopharmaceuticals and advanced nutrition, but one of the key benefits of our photomolecular platform is cost efficiency due to our use of light, which is the cheapest possible input into biology.
We’re co-developing the future of biology with innovators and leaders across biopharmaceuticals and advanced nutrition. Examples include proteins found in supplements and infant formula, antibodies to treat diseases, whole cuts of cultured meat, higher fidelity disease models, and other innovations never before possible.
At this stage, we’re focused on co-development partnerships, providing select partners with limited early access to our groundbreaking technology.
For proof-of-concept studies, we generally follow an R&D fee-for-service model, with clearly defined project milestones and associated costs.
For projects closer to commercialization, we offer a more flexible approach, which can include technical milestones, phased payments, and discussions around royalty payments for products produced with our photomolecular platform. Additionally, we can negotiate exclusive licenses for specific product categories, ensuring that your investment is fully protected and aligned with your long-term strategic goals.
Our business model varies from licensing the technology to joint ventures and offering customized optogenetics solutions or services to partners in the biotech and pharma industries. This flexibility allows us to adapt our approach to meet the specific requirements and strategic objectives of each partner.
We will be announcing commercial partners in the months ahead. Stay tuned…